Insulins and oral hypoglycemic medications

Pediatric Endocrinology Reviews

Volumn 2, Issue SUPPL. 1, 2004, Pages 153-162

  Hale, Daniel E ^a   Kiess, Wieland ^b  

^a University of Texas Health Science Center   (United States)

^b UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Acarbose; Glargine; Hyperglycemia; Hypoglycemia; Insulin; Insulin sensitizer; Lipoatrophy; Lipohypertrophy; Meglitinide; Metformin; Sulfonylurea; Thiazolidinedione; Type 1 diabetes mellitus (T1DM); Type 2 diabetes mellitus (T2DM); Uptake blocker

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ANTIDIABETIC AGENT; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCOSE UPTAKE BLOCKER; INSULIN; INSULIN ANTIBODY; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; INSULIN SECRETAGOGUE; INSULIN SENSITIZING AGENT; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; MEGLITINIDE; METFORMIN; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TETRAHYDROLIPSTATIN; UNCLASSIFIED DRUG;

ABDOMINAL CRAMP; ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ACANTHOSIS NIGRICANS; ADD ON THERAPY; ARTHRALGIA; BACKACHE; BODY WEIGHT DISORDER; CARDIOTOXICITY; CHILD; CHILDHOOD DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DIARRHEA; DRUG ABSORPTION; DRUG DOSE REGIMEN; DRUG INDICATION; EDEMA; ERYTHEMA; FLATULENCE; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INJECTION SITE REACTION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; INSULIN TREATMENT; JUVENILE DIABETES MELLITUS; LACTIC ACIDOSIS; LIPOATROPHY; LIPOHYPERTROPHY; LIVER DYSFUNCTION; MATURITY ONSET DIABETES MELLITUS; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRURITUS; RESPIRATORY TRACT DISEASE; REVIEW; SIDE EFFECT; SKIN TOXICITY; URTICARIA; VOMITING; WEIGHT GAIN;

ADMINISTRATION, ORAL; CHILD; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN;

EID: 12344316755     PISSN: 15654753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Danne T, Deiss O, Hopfenmuller W, von Schutz W, Kordonouri O. Experience with insulin analogues in children. Norm Res 2002;52(Supp 1)46-53
2. Chapman TM, Noble S, Goa KL. Insulin aspart: a review of its use in the management of type 1 and type 2 diabetes mellitus. Drugs 2002;62:1945-1981
3. Willi SM, Planton J, Egede L, Scnwartz S. Benefits of continuous subcutaneous insulin infusion in children with type 1 diabetes. J Pediatr 2003;143:796-801
4. Owens DR, Zinman B, Bolli CB. Insulins today and beyond. Lancet 2001;358:739-746
5. Bolli GB, Owens DR. Insulin glargine. Lancet 2000;356:443-445
6. Danne T, Lupke K, Walte K, Von Schuetz W, Gall MA. Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetes. Diabetes Care 2003;26:3087-3092
7. Vague P, Selam JL, Skeie S, De Leeuw I, Elte JW, Haahr H, Kristensen A, Draeger E. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 2003;26:590-596
8. Hermansen K, Madsbad S, Perrild H, Kristensen A, Axelsen M. Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy. Diabetes Care 2001;24:296-2301
9. Hamann A, Matthaei S, Rosak C, Silvestre L and the HOE901/4007 Study Group. A randomized clinical trial comparing breakfast, dinner or bedtime administration of insulin glargine in patients with type 1 diabetes. Diabetes Care 2003;26:1738-1744
10. Lepore M, Panpanelli S, Fanelli C, Porcellati F, Bartocci L, Di Vincenzo A, Cordoni C, Costa E, Brunetti P, Boulli GB. Pharmacokinetics and pharmacodynamics of subcutaneous insulin analogue glargine, NPH insulin and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000;49:2142-2148
11. Raskin P, Klaff L, Bergenstal R, Halle JP, Donley D, Mecca T. A 16-week comparison of the novel insulin analog insulin glargine (HOE901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care 2000;23:1666-1671
12. Skyler JS, Cefalu WT, Kourides IA, Landschultz WH, Balagtas CC, Chens SL, Gelfand RA. Efficacy of inhaled human insulin in type 1 diabetes mellitus: randomized proof-of-concept study. Lancet 2001;357:331-335
13. Chase HP, Dixon B, Pearson J, Fiallo-Scharer R, Watravens P, Klinsensmith G, Rewers M, Garg SK. Reduced hypoglycemic episodes and improved glycemic control in children with type 1 diabetes using insulin glargine and neutral protamine Hagedorn insulin. J Pediatr 2003;143:737-740
14. Donne T, Aman J, Schober E, Deiss D, Jacobsen JL, Friberg HH, Jensen LH, ANA 1200 Study Group. A comparison of postprandial and preprandial administration of insulin aspart in children and adolescents with type 1 diabetes. Diabetes Care 2003;26:2359-2364
15. Mortensen H, Lindhoilm A, Olsen B, Hyllebarg B. Rapid appearance and onset of action of insulin aspart in paediatric subjects with type 1 diabetes. Eur J Pediatr 2000;159:483-488
16. Rami B, Schober E. Postprandial glycemia after regular and lispro insulin in children and adolescents with diabetes. Eur J Pediatr 1997;156:838-840
17. Murphy NP, Keane SN, Ong KK, Ford-Adams M, Edge JA, Acerinin CL, Dunger DB. Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens. Diabetes Care 2003;26:799-804
18. Conrad SC, McGrath MT, Gitelman SE. Transition from multiple daily injections to continuous subcutaneous insulin infusion in type 1 diabetes mellitus. J Pediatr 2002;140:235-240
19. Willi SM, Planton J, Egede L, Schwarz S. Benefits of continuous subcutaneous insulin infusion in children with type 1 diabetes. J Pediatr 2003;143:796-801
20. Plotnick LP, Clark LM, Brancati FL, Erlinger T. Safety and effectiveness of insulin pump therapy in children and adolescents with type 1 diabetes. Diabetes Care 2003;26:1142-1146
21. Litton J, Rice A, Friedman N, Oden J, Lee MM, Freemark M. Insulin pump therapy in toddlers and preschool children with type 1 diabetes mellitus. J Pediatr 2002;141:490-495
22. Lenhard MJ, Reeves GD. Continuous subcutaneous insulin infusion: a comprehensive review of insulin pump therapy. Arch Intern Med 2001;161:2293-2300
23. Kaufman FR, Halvorson M, Fisher L, Pitukcheewanont P. Insulin pump therapy in type 1 pediatric patients. J Pediatr Endocrinol Metab 1999;12(Suppl3):759-764
24. Boehm BO, Home PD, Behrend C, Kamp NM, Lindholm A. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in Type 1 and Type 2 diabetic patients. Diab Med 2002;19:393-399
25. McSorfey PT, Bell PM, Jacobsen LV, Kristensen A, Lindholm A. Twice-daily biphasic insulin aspart 30 versus biphasic human insulin 30: a double-blind crossover study in adults with type 2 diabetes mellitus. Clin Therap 2002;24:30-39
26. Hermann LS. Optimising therapy for insulin-treated type 2 diabetes mellitus. Drugs & Aging 2000;17:283-294
27. Amin R, Ross K, Acerini CL, Edge JA, Warner J, Dunger DB. Hypoglycemia prevalence in prepubertal children with type 1 diabetes on standard insulin regimen: use of continuous glucose monitoring system. Diabetes Care 2003;26:662-667
28. Bergoda I, Suissa S, Dufresne J, Schriffin A. Severe hypoglycemia in IDDM children. Diabetes Care 1989;12:239-244
29. Jones TW, Davis EA. Hypoglycemia in children with type 1 diabetes: current issues and controversies. Pediatric Diabetes 2003;4:143-50
30. Felner EI. Human insulin-induced lipoatrophy. J Pediatr 2003;142:448
31. Purnell JQ, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA, Brunzelt JD. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial. JAMA 1998;280:140-6
32. Marshall MO, Heding LG, Villumsen J, Akerblom HK, Baevre H, Dahlquist G, Kjaergaard JJ, Knip M, Linderen F, Ludvigsson J: Development of insulin antibodies, metabolic control and B-cell function in newly diagnosed insulin dependent diabetic children treated with monocomponent human insulin or monocomponent porcine insulin. Diabetes Res 1988;9:169-175
33. Fineberg SE, Huang J, Brunell R, Gulliya KS, Anderson JH. Effect of long-term exposure to insulin lispro on the induction of antibody response in patients with type 1 or type 2 diabetes. Diabetes Care 2003;26:89-96
34. White NH, Cleary PA, Dahms W, Goldstein D, Malone J, Tamborlane WV. Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT). J Pediatr 2001;139:804-812
35. Wolfsdorf JI. Improving diabetes control in adolescents. Diabetes Care 1999;22:1767-1768
36. Szydlo D, van Wattum PJ, Woolston J. Psychological aspects of diabetes mellitus. Child & Adol Psych Clin North Amer 2003;12:439-458
37. American Diabetes Association: Clinical practice recommendations. Diabetes Care 2004;27(Suppl 1):S1-114
38. Peorson ER, Velno G, Clark P, Stride A, Shepherd M, Frayfing TM, Bulman MP, Ellard S, Froguel P, Hattersley AT. Beta-cell genes and diabetes: quantitative and qualitative differences in the pathophysiology of hepatic nuclear factor-1 alpha and glucokinase mutations. Diabetes 2001;50(Suppl 1):S101-107
39. Willi SM, Kennedy A, Brant BP, Wallace P, Rosers NL, Garvey WT. Effective use of thiazolidinediones for the treatment of glucocorticoid-induced diabetes. Diab Res Clin Pract 2003;58:87-96
40. Garber AJ, Donovan DS Jr, Dandona P, Bruce S, Park JS. Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes. J Clin Endocrinol Metab 2003;88:3598-3604
41. Clark CM Jr, Helmy AW. Clinical trials with glimepiride. Drugs Today 1998;34:401-408
42. Saloranta C, Hershon K, Ball M, Dickinson S, Holmes D. Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia. J Clin Endocrinol Metab 2002;87:4171-4176
43. Marre M, Van Goal L, Usadel KH, Ball M, Whatmough I, Guitard C. Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients. Diab Obes Metab 2002;4:177-186
44. Del Prato S, Heine RJ, Keilson L, Guitard C, Shen SG, Emmons RP. Treatment of patients over 64 years of age with type 2 diabetes: experience from nateglinide pooled database retrospective analysis. Diabetes Care 2003;26:2075-2080
45. Raskin P, Klaff L, McGill J, South SA, Hollander P, Khutoryansky N, Hale PM. Repaglinide vs. Nateglinide Metformin Combination Study Group. Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin. Diabetes Care 2003;26:2063-2068
46. Furlong NJ, Hulme SA, O'Brien SV, Hardy KJ. Repaglinide versus metformin in combination with bedtime NPH insulin in patients with type 2 diabetes established on insulin/metformin combination therapy. Diabetes Care 2002;25:1685-1990
47. Schmitz O, Lund S, Andersen PH, Jonler M, Porksen N. Optimizing insulin secretagogue therapy in patients with type 2 diabetes: a randomized double-blind study with repaglinide. Diabetes Care 2002;25:342-346
48. Jovanovic L, Dailey G III, Huang WC, Strange P, Goldstein BJ. Repaglinide in type 2 diabetes: a 24-week, fixed-dose efficacy and safety study. J Clin Pharmacol 2000;40:49-57
49. Goldberg RB, Einhorn D, Lucas CP, Rendell MS, Damsbo P, Huang WC, Strange P, Brodows RG. A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes. Diabetes Care 1998;21:1897-1903
50. Marbury T, Huang WC, Strange P, Lebowitz H. Repaglinide versus glyburide: a one-year comparison trial. Diabetes Res Clin Pract 1999;43:155-166
51. Landgraf R, Bilo HJ, Muller PG. A comparison of repaglinide and glibenclamide in the treatment of type 2 diabetic patients previously treated with sulphonylureas. Eur J Clin Pharmacol 1999;55:165-17
52. Wolffenbuttel BH, Landgraf R. A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes: Dutch and German Repaglinide Study Group. Diabetes Care 1999;22:463-477
53. Moses R, Slobodniuk R, Boyages S, Cotagiuri S, Kidson W, Carter J, Donnelly T, Moffitt P, Hopkins H. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 1999;22:119-124
54. Raskin P, Jovanovic L, Berger S, Schwartz S, Woo V, Ratner R. Repaglinide/troglitazone combination therapy: improved glycemic control in type 2 diabetes. Diabetes Care 2000;23:979-983
55. Anonymous. Type 2 diabetes in children and adolescents. Diabetes Care 2000;23:381-389
56. Hamilton J, Cummings E, Zdravkovic V, Finegood D, Daneman D. Metformin as an adjunct therapy in adolescents with type 1 diabetes and insulin resistance: a randomized control trial. Diabetes Care 2003;26:138-143
57. Ehrmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfietd RL, Polonsky KS. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metabol 1997;82:524-530
58. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM, Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403
59. Lehtovirta M, Forsén B, Gullström M, Häggblom M, Eriksson JG, Taskinen M-R, Groop L. Metabolic effects of metformin in patients with impaired glucose tolerance. Diabet Med 2001;18:578-583
60. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroqwn A, Goico J, Ochoa C, Tan S, Berkowitz K, Hodis HN, Azen SP. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002;51:2796-2803
61. Ovalle F, Bell DS. Clinical evidence of thiazolidinedione-induced improvement of pancreatic beta-cell function in patients with type 2 diabetes mellitus. Diab Obes Metab 2002;4:56-9
62. Radziuk J, Bailey CJ, Wiernsperger NF, Yudkin JS. Metformin and its liver targets in the treatment of type 2 diabetes. Current Drug Targets - Immune Endocrine & Metabolic Disorders 2003;3:151-169
63. Mathieu-Costello O, Kong A, Ciaraldi TP, Cui L, Ju Y, Chu N, Kim D, Mudaliar S, Henry RR. Regulation of skeletal muscle morphology in type 2 diabetic subjects by troglitazone and metformin: relationship to glucose disposal. Metabolism 2003;52:540-546
64. Diamant M, Heine RJ. Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. Drugs 2003;63:1373-1405
65. Gurnell M, Savage DB, Cnatterjee VK, O'RahiKy S. The metabolic syndrome: peroxisome proliferator-activated receptor gamma and its therapeutic modulation. J Clin Endocrinol Metab 2003;88:2412-2421
66. Lupi R. Del Guerra S. Marselli L. Bugliani M. Boggi U. Mosca F. Marchetti P. Del Prato S. Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARgamma2 in the modulation of insulin secretion. Amer J Physiol 2004;286:E560-567
67. Stades AM, Heikens JT, Erkelens DW, Holleman F, Hoekstra JB. Metformin and lactic acidosis: cause or coincidence? A review of case reports. J Int Med 2004;255:179-87
68. Salpeter SR, Greyber E, Pasternak GA, Salpeter SE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis. Arch Intern Med 2003;163:2594-2602
69. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis. Arch Intern Med 2003;16:2594-2602
70. Nesta RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Norton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R. American Heart Association. American Diabetes Association. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 2003;108:2941-2948
71. Jones KL, Arslanian S, Peterokova VA, Park JS, Tomlinson MJ. Effect of metformin in pediatric patients with type 2 diabetes: a randomized controlled trial. Diabetes Care 2002;25:89-94
72. Scneen AJ. Clinical efficacy of acarbose in diabetes mellitus: a critical review of controlled trials. Diab Metab 1998;24:311-320